Skip to main content

Table 1 Major clinical trials of elotuzumab that have published data

From: Elotuzumab for the treatment of multiple myeloma

Study

NCT number (trial name)

Phase

N

Regimen

ORR

PFS rate

Median PFS (months)

Zonder 2012 [23]

NCT00425347

(HuLuc63-1701)

1

35a

Elotuzumab (0.5–20 mg/kg)

0

–

–

Lonial 2012 [26, 27]

NCT00742560

(HuLuc63-1703)

1b

29b

Elotuzumab (5–20 mg/kg) + Rd

82 %

–

32.9

Richardson 2015 [27]

NCT00742560

(HuLuc63-1703)

2

36

Elotuzumab (10 mg/kg) + Rd

92 %

 

32.5c

37

Elotuzumab (20 mg/kg) + Rd

76 %

 

25.0c

Lonial 2015 [32]

NCT01239797

(ELOQUENT-2)

3

321

Elotuzumab (10 mg/kg) + Rd

79 %

1-year 68 %, 2-year 41 %

19.4

325

Rd

66 %

1-year 57 %, 2-year 27 %

14.9

Mateos 2014 [34]

NCT01632150

2

40

Elotuzumab (10 mg/kg) + TDd

40 %

–

–

Jakubowiak 2012 [35]

NCT00726869

(HuLuc63-1702)

1

28

Elotuzumab (2.5–20 mg/kg) + V

48 %

 

9.46e

Palumbo 2015 [38]

Jakubowiak 2016 [39]

NCT01478048

1/2

77f

Elotuzumab (10 mg/kg) + VD

66 %

1-year 39 %, 2-year 18 %

9.7

75

VD

63 %

1-year 33 %, 2-year 11 %

6.9

  1. N number; ORR objective response rate; PFS progression-free survival; Rd lenolidomide and dexamethasone; TD thalidomide and dexamethasone; V bortezomib; VD bortezomib and dexamethasone
  2. aThirty-four patients treated
  3. bTwenty-eight patients treated
  4. cMedian time to progression or death
  5. dCyclophosphamide was added if progressing between cycle 2 and 5 or not responding by cycle 5
  6. eMedian time to progression
  7. fSeventy-five patients treated